Beruflich Dokumente
Kultur Dokumente
Hormonal
Gabriel Molina
Kevin Murillo
Marco Quiros
Ral Vargas
Indice
Generalidades
Mortalidad
Efecto Cardiovascular
Osteoporosis
Cancer
Menopausia
Indicacin
Menopausia temprana
Contraindicacin
Ca de mama
Enfermedad cardiovascular
Coronaria y ECV
Eventos tromboemblicos
Trombofilias
TRH
Primeros 5 aos.
17B-estradiol (0,5mg/d).
ACOs
Calidad de vida.
Disminuye mortalidad
Efecto Cardiovascular
Peso corporal
Disminucin significativa
No aumento
Ginecoide
DM-2
Sensibilidad a la insulina
Metabolismo de lpidos
WHI y HERS
TRH y osteoporosis
Tulay Okman-Kilic (2015). Estrogen Deficiency and Osteoporosis. Advances in Osteoporosis. Yannis Dionyssiotis (Ed.), InTech
Qaseem A, Snow V, Shekelle P, Hopkins R, Forciea M, Owens D. Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical
Practice Guideline from the American College of Physicians. Ann Intern Med.2008;149(6):404-415.
WHI n=16.608
HERS n= 2.763
Landa M. Papel de la terapia hormonal sustitutiva, en la prevencin y tratamiento de la osteoporosismenopusica. Anales Sis San
Navarrav.26supl.3Pamplona2003
MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic Review: Comparative Effectiveness of Treatments to
Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis. Ann Intern Med.2008;148(3):197-213.
MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic Review: Comparative Effectiveness of Treatments to
Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis. Ann Intern Med.2008;148(3):197-213.
MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic Review: Comparative Effectiveness of Treatments to
Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis. Ann Intern Med.2008;148(3):197-213.
MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic Review: Comparative Effectiveness of Treatments to
Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis. Ann Intern Med.2008;148(3):197-213.
MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic Review: Comparative Effectiveness of Treatments to
Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis. Ann Intern Med.2008;148(3):197-213.
MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic Review: Comparative Effectiveness of Treatments to
Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis. Ann Intern Med.2008;148(3):197-213.
MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic Review: Comparative Effectiveness of Treatments to
Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis. Ann Intern Med.2008;148(3):197-213.
Pacientes sin fractura previa pero con diagnstico de osteoporosis por DXA.
Pacientes con densidad mineral baja, hasta hace 5 aos llamada osteopenia,
(T-score -1.0 y > -2.5 DS) y evaluacin FRAX con 20% de probabilidad a 10
aos de fracturas osteoporticas mayor y/o 3 % de probabilidad a 10 aos
para fractura de cadera.
El FRAX es un modelo que integra diversos factores de riesgo para fractura, desarrollado por la OMS y se encuentra disponible
en lnea www.sheffield.ac.uk/FRAX/.
Los resultados de los ltimos ensayos aleatorizados doble ciego (HERS, WHI)
recomiendan tratamientos menores de 5 aos por incremento de
Accidentes cardiovasculares
Ictus
Tromboembolia venosa
Cncer de mama.
Fue detenido prematuramente (tras 5,2 aos) porque los resultados sugeran
que el riesgo de salud exceda los beneficios.
From: Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative
Randomized Trial
JAMA. 2003;289(24):3243-3253. doi:10.1001/jama.289.24.3243
From: Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative
Randomized Trial
JAMA. 2003;289(24):3243-3253. doi:10.1001/jama.289.24.3243
Figure Legend:
Hazard ratios (HRs) are from unweighted Cox proportional hazardsregression models, stratified by age and dietary modification randomizationgroup. Z statistics and P values
are from weightedCox proportional hazards regression models, stratified by age and dietarymodification randomization group. CI indicates confidence interval.
CNCER DE ENDOMETRIO
TRH
Terapia
combinanada
contnua
Sin tx
estrgenos
tibolona
cclica
IMC
969 M
DX CA ENDOMETRIO
45-74
TRHc
1325 M
CONTROL
NO TRH
TRH
VS
NO TRH
RR 0.6
TRH
VS
RR 0.2
TRH
VS
TRHci
RR 0.3
WHI.
8506
TRH
8102
EEC
AMP
PLACEBO
RR 0.83
MWS
716 738 M
Postmeno
pusicas
No CA, No H
1320 DX CA ENDOM
22% TX COMBINADA C
TRH
45%
45% TX C COMBINADA
9% TIBOLONA Y 4% E
NO TRH 45%
3-4a
TRHcom
VS
NO TRH
0.71
TRHc
VS
NO TRH
~1
RR 1.05, 0.91-1.22
IMC
25 R
NO TRH
Ovarian cancer and hormone replacement therapy in the Million Women Study.
CA OVARIO
948 576
No Ca previo, ni
oforectoma bi
50% Ocas
30% UA
TRH RR 1,11
>10 a
TRH RR 1,31
~ 57.2
CA OVARIO
Los ACO se asocian a disminucin del riesgo en premenopasicas, pero aumento en las
postmenopusicas